Drugs / MK-2060
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06582602 | Oct 2024 → Apr 2025 | venous thromboembolism | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05769595 | Jun 2023 → Feb 2024 | chronic renal failure syndrome, end stage renal failure | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06843993 | Mar → Oct 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05656040 | Feb 2023 → Aug 2024 | chronic renal failure syndrome, end stage renal failure | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05335005 | May 2022 → Feb 2023 | chronic renal failure syndrome, end stage renal failure | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03873038 | Apr 2019 → Dec 2021 | end stage renal failure | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05027074 | Sep 2021 → Oct 2024 | chronic renal failure syndrome, end stage renal failure | Merck Sharp & Dohme LLC | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-08-23 | Merck Sharp & Dohme LLC | Regulatory Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy merck.com ↗
Merck, (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck’s investigational anticoagulant therapy MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-23 | Merck Sharp & Dohme LLC | Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy merck.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06582602 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody against Factor XI” NCT05027074 ↗ |
| Route | Intravenous | “administered via IV infusion” NCT03873038 ↗ |